This study investigated the fire needle and phototherapy combination for treating vitiligo through a meta-analysis of the published literature. Indeed, vitiligo is a common chronic skin condition characterized by the appearance of white patches. It is the most prevalent disorder, affecting approximately 1% of the global population. There is no known cure or clinical recommendation for treating vitiligo. The majority of medical guidelines suggest vitiligo treatment with the use of fire needles. Here, vitiligo was treated with a novel mechanism combining a fire needle with phototherapy. The handheld phototherapy devices include a fire needle option for disease treatment. Miniature lesions that could be used to detect and treat vitiligo at an early stage could be managed by hybrid-capable devices. The real-time study included more than 3,435 patients. The dosages were altered to control the adverse effects. Following treatment, granulation tissues developed on the injured skin, diminishing the shallow area and wound surface. The case studies demonstrate that combining phototherapy and fire needle therapy is more practical than the other methods.

Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by polymorphous eruption and pruritus, while persistent scratching results in lichenification and prurigo nodularis (PN). It is mainly mediated by Th2 immune responses, of which Th2 cytokines IL-4, IL-13 and IL-31 are crucial. 1 Dupilumab is a new biological agent that blocks IL-4/IL-13 signaling by binding to the shared alpha subunit of IL-4 and IL-13 receptors, resulting in a downregulation of receptor signaling downstream JAK-STAT pathway. 2 Dupilumab was effective for difficult-to-treat-PN-like clinical presentation of AD. 3 We report a